Bristol Myers Squibb (BMY) Doubles MRD—Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM
Bristol Myers Squibb reported EXCALIBER-RRMM showed ZENBEXUS with daratumumab/dexamethasone achieved 41.1% MRD—negative CR vs 20.7% with DVd (p<0.0001) at 15.7 months’ median follow-up in 420 patients. PFS, the co—primary endpoint, is still being evaluated.Material DetailsContext by AI AnalystThis…